Abstract | REASONS FOR PERFORMING STUDY: OBJECTIVES:
Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety. METHODS: Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4-1 mg/kg (mean 0.5 mg/kg) trilostane once daily. RESULTS: Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 +/- 53.0 nmol/l) and after (130 +/- 46.1 nmol/l) trilostane. CONCLUSIONS:
Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration. POTENTIAL RELEVANCE:
|
Authors | C M McGowan, R Neiger |
Journal | Equine veterinary journal
(Equine Vet J)
Vol. 35
Issue 4
Pg. 414-8
(Jun 2003)
ISSN: 0425-1644 [Print] United States |
PMID | 12880011
(Publication Type: Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Dihydrotestosterone
- Adrenocorticotropic Hormone
- 3-Hydroxysteroid Dehydrogenases
- trilostane
- Hydrocortisone
|
Topics |
- 3-Hydroxysteroid Dehydrogenases
(antagonists & inhibitors)
- Adrenocorticotropic Hormone
(blood)
- Animals
- Cushing Syndrome
(drug therapy, veterinary)
- Dihydrotestosterone
(analogs & derivatives, therapeutic use)
- Enzyme Inhibitors
(therapeutic use)
- Female
- Horse Diseases
(drug therapy)
- Horses
- Hydrocortisone
(blood)
- Male
- Safety
- Treatment Outcome
|